

**Kanabo Group PLC**  
("Kanabo" or the "Company")

**Resignation of Director**

London, UK - March 24, 2025 - Kanabo Group PLC, a leader in digital health services and specialised medicines (including medicinal cannabis), announces that Ian Mattioli, Non-Executive Director of the Company, has resigned with immediate effect.

Due to health and personal reasons, Ian will spend more time committed to his other business interests and the Board takes the opportunity to thank Ian for his commitment to the Company during his tenure.

**Enquiries:**

**Kanabo Group plc** +44 (0)20 7469 0930  
Avihu Tamir, Chief Executive Officer  
Odelia Vazana, Chief Financial Officer

**Peterhouse Capital Limited (Financial Adviser and Broker)** +44 (0)20 7469 0930  
Guy Miller / Lucy Williams / Charles Goodfellow

**About Kanabo Group plc (LSE: KNB)** Kanabo Group plc is a digital health company committed to improving patient care through its specialised technology platform and treatments, including medicinal cannabis.

Kanabo's NHS-approved telehealth platform, The GP Service, provides video consultations, online prescriptions, and comprehensive primary care. Treat It, the Company's specialised clinic, extends these services to chronic pain management and mental health indications, offering patients access to secondary care.

With two complementary business divisions, Kanabo delivers end-to-end digital health solutions, from telehealth consultations and prescriptions to tailored treatments. Its partially owned subsidiary, Kanabo Agritec Ltd, offers cultivation consultancy, enabling reliable access to high-quality raw materials for Kanabo's product range.

Kanabo Group plc remains focused on delivering high-quality medical solutions that make healthcare more accessible for patients across the UK and beyond.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAEAFDLAEESEFA